Endothelial function assessed by peripheral arterial tonometry is not related with FGF23 serum levels in pre-dialysis CKD patients

A função endotelial avaliada pela tonometria arterial periférica não se correlaciona com os níveis séricos de FGF-23 em doentes renais crónicos pré-diálise

Ana Cerqueira1,2,3, Janete Queihas-Santos2,3, Manuel Pestana1,2,3

1 Department of Nephrology, São João Hospital Center, EPE. Porto, Portugal
2 Department of Renal, Urological and Infectious Diseases, Faculty of Medicine, University of Porto. Porto, Portugal
3 Nephrology and Infectious Diseases Research and Development Group, INEB, University of Porto. Porto, Portugal

Endothelial function assessed by peripheral arterial tonometry is not related with FGF23 serum levels in pre-dialysis CKD patients

ABSTRACT

Cardiovascular (CV) diseases are the leading causes of morbidity and mortality in patients with chronic kidney disease (CKD) that encompass the mildest degrees of renal impairment. High levels of phosphate and fibroblast growth factor 23 (FGF-23) are associated with increased CV events in this population. However, differences in clinical and pathological manifestations have suggested that distinct mechanisms may underlie cardiovascular events associated with high phosphate and FGF-23 serum levels. In animal studies endothelial dysfunction (ED) has recently been associated with increased levels of phosphorus, but not with the increase of FGF-23 serum levels. In this study, we aimed to assess endothelial function and the relationship with phosphate and FGF23 serum levels in a pre-dialysis CKD population. We examined 43 CKD patients in stages 1 to 5, followed-up in our outpatient clinic. Blood pressure, renal function, proteinuria, phosphate serum levels and Charlson Index were evaluated in the studied population. The FGF-23 levels were assessed by ELISA. Endothelial function was assessed by peripheral arterial tonometry (Endo-Pat 2000) where lower reactive hyperaemia index (RHI) values correspond to greater ED. Estimated GFR (eGFR) negatively correlated either with both serum phosphate ($r = -0.42; p < 0.0004$), and circulating FGF-23 levels ($r = -0.42; p < 0.05$); RHI positively correlated with eGFR ($r = 0.35; p < 0.03$) and negatively correlated with age ($r = -0.59; p < 0.0001$), proteinuria ($r = -0.50; p < 0.03$), serum phosphate ($r = -0.34; p < 0.04$) and Charlson index ($r = -0.56; p < 0.0003$). However, no significant relationship was observed between RHI and FGF23 serum levels ($r = -0.11$, n.s.) in the studied population. Our results suggest that peripheral arterial tonometry, a non-invasive method for evaluation of the endothelial function, can be a practical tool that adds clinically useful information to improve risk stratification in CKD pre-dialysis patients. Our results also agree with the view that phosphate and FGF-23 serum levels might contribute to increased cardiovascular risk in CKD through distinct mechanisms.

Key-Words: Cardiovascular risk; chronic kidney disease; endothelial function; FGF-23; phosphate; tonometry.
INTRODUCTION

Chronic kidney disease (CKD) is strongly associated with cardiovascular disease and a graded inverse relationship between estimated glomerular filtration rate (eGFR) and cardiovascular event rates has emerged from large-scale observational studies. As cardiovascular diseases are the leading cause of death in CKD patients, it is of great importance to have instruments to stratify cardiovascular risk in these populations. Although classic cardiovascular risk factors are almost universally present in CKD, they cannot account for the increased CV risk in these patients.

Disturbances in phosphate homeostasis occur in most CKD patients and growing evidence suggests that hyperphosphatemia is associated with increased all-cause mortality and cardiovascular events in this population. Hyperphosphatemia correlates with the calcification of coronary arteries and cardiac valves. In addition, in vitro studies have shown that phosphate induces vascular calcification and accelerates the osteogenic transformation of vascular smooth muscle cells.

RESUMO

As doenças cardiovasculares são a principal causa de morbidade e mortalidade na doença renal crónica (DRC), mesmo nos estádios mais precoces. Os aumentos da fosfatemia e dos níveis séricos do factor de crescimento dos fibroblastos 23 (FGF-23) associam-se ambos a um aumento dos eventos cardiovasculares na DRC. No entanto, diferenças na tradução clínica e patológica, têm vindo a sugerir a existência de mecanismos distintos, para explicar os eventos cardiovasculares associados à hiperfosfatemia e ao aumento dos níveis séricos de FGF-23. Em estudos animais, a disfunção endotelial (DE) foi recentemente associada ao aumento dos níveis de fosfato, mas não ao aumento do FGF-23. O presente estudo avaliou a função endotelial e a sua relação com os níveis séricos de fósforo e de FGF-23 em doentes com DRC pré-diálise.

Não se verificou relação entre o RHI e os níveis séricos de FGF-23 (r = -0,11; ns) na população estudada. Os nossos resultados sugerem que a tonometria arterial periférica, um método não-invasivo para avaliação da função endotelial, pode constituir uma ferramenta útil na prática clínica contribuindo para estratificar o risco cardiovascular na DRC pré-diálise. Para além disso, os nossos dados apoiam a hipótese de que a influência do fósforo sérico e do FGF-23 na doença vascular pode ser mediada por mecanismos distintos.

Palavras-Chave: Doença renal crónica; função endotelial; fósforo; FGF-23; risco cardiovascular; tonometria.
Endothelial dysfunction (ED) represents the earliest abnormality in the development of vascular disease linked to atherosclerosis. Pulse tonometry is a rapid, non-invasive and non-operator-dependent technique to assess endothelial vasodilator function and peripheral endothelial function assessed by Endo-PAT was found to be an independent predictor of cardiovascular events in CKD patients.

To the extent that the increase in serum phosphorus levels but not high levels of FGF-23 serum levels have been implicated as mechanism of ED in CKD, we aimed to examine endothelial function using Endo-PAT in a pre-dialysis CKD population and the relationship with both FGF-23 and phosphate serum levels.

METHODS

We examined 43 CKD patients followed-up in our outpatient clinic of the Nephrology department of the “Centro Hospitalar de São João”. The patients were distributed according to the GFR calculated by CKD-EPI formula (stage 1: > 90mL/min/1.73m²; stage 2: between 60-89mL/min/1.73m²; stage 3: between 30-59mL/min/1.73m²; stage 4: between 15-29 mL/min/1.73m²; stage 5: < 15 mL/min/1.73m²). Patients were studied in standard conditions (no changes were made in their usual medication, nor have extra reinforcement of diet restrictions or smoke abstinence been done). The patients were randomly selected, without previous knowledge, in their routine appointment, after being informed about the purpose and methods of the study giving voluntarily their written informed consent. Patients with arteriovenous fistula (which prevents evaluation with Endo-PAT), acute kidney injury, recent hospital admission (< 2 weeks), recent infections (< 1 week) and known psychiatric disturbances were excluded from the study.

The research was approved by the Ethics Committee for Health and the Local Institutional Review Board of São João Hospital Centre, and was carried out in accordance with the Declaration of Helsinki of the World Medical Association.

Blood and urine samples were collected in all participants. Blood pressure, renal function, proteinuria, phosphate serum levels and a validated comorbidity index (Charlson Index) were evaluated in the studied population. Intact FGF-23 levels were assessed by an ELISA kit (Immutopics, Inc.).

Endothelial function was assessed by peripheral arterial tonometry (Endo-Pat 2000). The Endo-Pat serve as a measure of peripheral vasomotor function, in which nitric oxide has shown to be an important contributor as was validated in the large, community-based Framingham study. The technique provides values for the calculation of a reactive hyperaemia index (RHI), which gives an indication of the endothelial vasodilator function. The RHI is the post-to-pre occlusion PAT signal ratio in the occluded arm, relative to the same ratio in the control arm, and corrected for baseline vascular tone. Lower RHI values correspond to greater ED.

STATISTICS

All data are presented as means ± SEM. A p < 0.05 was assumed to denote a significant difference.

RESULTS

The demographic and clinical characteristics of the studied population are presented in Table 1. The patients were distributed according to the eGFR calculated by CKD-EPI formula as: CKD stages 1-2 [n =
Endothelial function assessed by peripheral arterial tonometry is not related with FGF23 serum levels in pre-dialysis CKD patients

Table 1
Demographic and clinical data corresponding to the three distinct groups.

<table>
<thead>
<tr>
<th></th>
<th>CKD stage 1-2 (n = 16)</th>
<th>CKD stage 3 (n = 14)</th>
<th>CKD stage 4-5 (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>48.6 ± 3.2</td>
<td>58.0 ± 3.4</td>
<td>59.8 ± 3.2†</td>
</tr>
<tr>
<td>Male (%)</td>
<td>37</td>
<td>53</td>
<td>33</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>161.2 ± 2.5</td>
<td>160.5 ± 2.2</td>
<td>165.1 ± 2.8</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>70.8 ± 4.2</td>
<td>75.1 ± 5.0</td>
<td>78.7 ± 5.6</td>
</tr>
<tr>
<td>Tobacco use (n)</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td><strong>Clinical data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aetiology of CKD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Glomerulonephritis (%)</td>
<td>50</td>
<td>36</td>
<td>15</td>
</tr>
<tr>
<td>Polycystic Kidney Disease (%)</td>
<td>19</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Diabetic Nephropathy (%)</td>
<td>13</td>
<td>14</td>
<td>38</td>
</tr>
<tr>
<td>Undetermined (%)</td>
<td>13</td>
<td>14</td>
<td>23</td>
</tr>
<tr>
<td>Others (%)</td>
<td>6</td>
<td>29</td>
<td>15</td>
</tr>
<tr>
<td><strong>Antihypertensive drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta blockers (%)</td>
<td>13</td>
<td>29</td>
<td>38</td>
</tr>
<tr>
<td>ACE inhibitors (%)</td>
<td>63</td>
<td>64</td>
<td>46</td>
</tr>
<tr>
<td>Angiotensin receptor antagonists (%)</td>
<td>63</td>
<td>43</td>
<td>31</td>
</tr>
<tr>
<td>Calcium channel blockers (%)</td>
<td>13</td>
<td>21</td>
<td>46</td>
</tr>
<tr>
<td><strong>Cholecalciferol</strong></td>
<td>4</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td><strong>Activated D vitamin</strong></td>
<td>0</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td><strong>Phosphate binder (calcium carbonate)</strong></td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>Other clinical relevant data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CKD-EPI (ml/min/1.73m²)</td>
<td>92.9 ± 5.1</td>
<td>45.1 ± 2.5⁺</td>
<td>20.6 ± 1.4⁸⁺</td>
</tr>
<tr>
<td>High Blood Pressure, BP (%)</td>
<td>69</td>
<td>93</td>
<td>77</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>130.1 ± 4.7</td>
<td>136.6 ± 6.2</td>
<td>140.8 ± 6.2</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>77.9 ± 2.7</td>
<td>79.9 ± 3.8</td>
<td>74.5 ± 2.0</td>
</tr>
<tr>
<td>DM (%)</td>
<td>25</td>
<td>29</td>
<td>46</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.9</td>
<td>29.2</td>
<td>27.8</td>
</tr>
<tr>
<td>Charlson Index</td>
<td>1.8 ± 0.6</td>
<td>5.1 ± 0.6</td>
<td>5.3 ± 0.6†</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD.

Results were considered significant if \( p < 0.05 \), and signalled as follow: * stages 1-2 vs. 3, † stages 1-2 vs. 5-4, ⁺ stages 3 vs. 5-4.

16, M37%, age 48.6 ± 3.2], CKD stage 3 [n = 14, M33%, age 58.0 ± 4.1], CKD stages 4-5 [n = 13, M33%, age 59.8 ± 4.0]. Demographic characteristics only achieved statistically significant differences concerning patients' age [CKD stages 1-2 vs. 5-4 (48.6 ± 3.2 vs. 59.8 ± 4.0, \( p < 0.05 \)). No significant differences were observed among the three groups regarding CKD aetiology, prescribed antihypertensive drugs, body mass index (BMI), diabetes (DM) and hypertension prevalences. As expected, the Charlson Index was significantly higher in stages 4-5 group than in stages 1-2 group (5.3 ± 0.6 vs. 1.8 ± 0.6; \( p < 0.05 \)).

The biochemical and other analytical parameters of the studied population are presented in Table 2. As expected, we found statistically significant differences among the three groups, regarding haemoglobin level, urinary protein/creatinine ratio, serum phosphate levels, iPTH, FGF-23, uric acid and brain natriuretic peptide.

Concerning endothelial function assessed by EndoPat, RHI was found significantly lower in CKD stages 4-5 in comparison with CKD stages 1-2 (1.60 ± 0.18 vs. 2.22 ± 0.16, \( p < 0.05 \)) (Fig. 1). In unadjusted analysis, RHI positively correlated with eGFR (\( r = 0.35; p < 0.04 \)) and negatively correlated with age (\( r = -0.59; p < 0.0001 \)), proteinuria (\( r = -0.50; p < 0.03 \)), phosphate serum levels (\( r = -0.34; p < 0.04 \)) and Charlson index (\( r = -0.56; p < 0.0003 \)) (Fig. 2).

In addition, in unadjusted analysis eGFR negatively correlated with FGF-23 (\( r = -0.42; p < 0.05 \)), phosphate serum levels (\( r = -0.42; p < 0.0004 \)), Charlson index (\( r = -0.63; p < 0.0001 \)) and age (\( r = -0.45; p < 0.003 \)) (Fig. 2). In the multivariate analysis, the
relationships of eGFR with both phosphate serum levels and FGF-23 persisted after adjustment for demographic and clinical variables associated with reduced renal function (Table 3).
DISCUSSION

The search for biomarkers that could explain or characterize the enhanced CV risk in CKD patients is of utmost importance and has gained prominence in the last few years. In relation with this subject, ED has been proposed as an early event of pathophysiological relevance in the atherosclerotic process that relates to higher risk of CV events in CKD. In the present study, carried out in a pre-dialysis CKD population, we confirmed that the decrease of renal function is associated with increased ED. In addition, we found in our pre-dialysis CKD patients that ED assessed by pulse tonometry also correlated positively with age, high scores of Charlson comorbidity index, increased proteinuria and high levels of serum phosphate. Since ED can be reversed or improved by lifestyle modifications and medical therapies, our results suggest that pulse tonometry, a non-invasive method for evaluation of ED, may add clinically useful information to improve risk stratification in CKD pre-dialysis patients, thus contributing to better follow-up of this population.

Another interesting finding of our study is that, in contrast to serum phosphate levels, circulating FGF-23 levels were not associated with ED. This dissociation, when viewed collectively with the observations that implicate circulating FGF-23 levels in the increased CV risk and mortality in CKD, lends further support to the view that targeting FGF-23 may not be useful in the prevention and management of uraemic vascular disease.

Our results fit well with recent findings in animal studies showing that incubation of cultured endothelial cells with high phosphate concentrations induces apoptosis, stimulates production of reactive oxygen species and impairs secretion of NO in response to acetylcholine, whereas the effect linking higher levels of FGF-23 with cardiovascular disease is independent of serum phosphate levels and mainly implicates the development of left ventricular hypertrophy. This study has the virtue of extrapolating to humans, the recent observations in animal studies that suggested that FGF-23 and serum phosphate promote distinct mechanisms of cardiovascular toxicity. Further investigation is needed to confirm these data and explore the pathophysiological mechanisms that underlie the increased cardiovascular risk associated with high phosphate and FGF-23 serum levels in CKD.

ACKNOWLEDGEMENTS

Supported by a clinical research grant from Sociedade Portuguesa de Nefrologia (project titled “Human renalase: relationship with mechanisms involved in increased cardiovascular risk in chronic kidney disease”) and PEst-OE/SAU/UI0725/2014 from FCT/COMPETE/FEDER.

Conflict of interest statement: All the authors declare that there is no conflict of interest.
Figure 2

Endothelial function assessed by peripheral arterial tonometry in CKD patients in stages 1 to 5 and its correlation between eGFR (A), Charlson index (B), phosphate (C), and FGF-23 levels (D). The eGFR and its correlation between phosphate (E), FGF-23 levels (F), Charlson index (G) and age (H).

References


Correspondence to:
Drª Ana Cerqueira
Department of Nephrology
São João Hospital Center, EPE
Alameda Prof. Hernâni Monteiro
4200-319, Porto, Portugal.
Email: anacerqueira-1@hotmail.com